Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Osteoporosis screening, HRT "reasonably cost-effective," OTA says.

This article was originally published in The Gray Sheet

Executive Summary

OSTEOPOROSIS SCREENING, HORMONE REPLACEMENT THERAPY "REASONABLY COST-EFFECTIVE" as prophylaxis against hip fracture and heart disease, an Aug. 29 Office of Technology Assessment background paper maintains. Entitled "Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy," the background paper was requested by the Senate Special Committee on Aging and the House Select Committee on Aging. The analysis looks at several osteoporosis treatment options, focusing primarily on two regimens that call for either bone mineral density screening coupled with targeted HRT or, alternatively, HRT for all post-menopausal women.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT004686

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel